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Circulating Melanoma Cell Subpopulations: Their
Heterogeneity and Differential Responses to
Treatment
Elin S. Gray1, Anna L. Reid1, Samantha Bowyer2, Leslie Calapre1, Kelvin Siew2, Robert Pearce1,
Lester Cowell3, Markus H. Frank1,4, Michael Millward2,5 and Mel Ziman1,6
Metastatic melanoma is a highly heterogeneous tumor; thus, methods to analyze tumor-derived cells circulating
in blood should address this diversity. Taking this into account, we analyzed, using multiparametric ﬂow
cytometry, the co-expression of the melanoma markers melanoma cell adhesion molecule and melanoma-
associated chondroitin sulphate proteoglycan and the tumor-initiating markers ATP-binding cassette sub-family B
member 5 (ABCB5), CD271, and receptor activator of NF-κβ (RANK) in individual circulating tumor cells (CTCs)
from 40 late-stage (III–IV) and 16 early-stage (I–II) melanoma patients. CTCs were heterogeneous within and
between patients, with limited co-expression between the ﬁve markers analyzed. Analysis of patient matched
blood and metastatic tumors revealed that ABCB5 and RANK subpopulations are more common among CTCs
than in the solid tumors, suggesting a preferential selection for these cells in circulation. Pairwise comparison of
CTC subpopulations longitudinally before and 6–13 weeks after treatment initiation showed that the percentage
of RANK+ CTCs signiﬁcantly increased in the patients undergoing targeted therapy (N= 16, Po0.01). Moreover,
the presence of ⩾ 5 RANK+ CTCs in the blood of patients undergoing targeted therapies was prognostic of
shorter progression-free survival (hazards ratio 8.73, 95% conﬁdence interval 1.82–41.75, Po0.01). Taken together,
our results provide evidence of the heterogeneity among CTC subpopulations in melanoma and the differential
response of these subpopulations to targeted therapy.
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INTRODUCTION
Melanoma is an aggressive cancer, which is responsible for
80% of skin cancer–related deaths. Most melanoma patients
are cured after surgical excision of the primary tumor, but 10–
20% of patients progress to develop metastatic disease.
Metastatic melanoma has a tendency to spread rapidly and
be intrinsically resistant to chemotherapy. Over the last 3
years, the implementation of targeted therapies and
immunotherapies has slowed down the progression of meta-
static melanoma in many patients. However, patients on
targeted therapies develop drug resistance within months after
treatment, and immunotherapies are only effective in a
proportion of patients (Homet and Ribas, 2014). Currently,
our ability to monitor recurrence and to predict treatment
efﬁcacy is limited. Future treatment decisions might be improved
by the use of biomarkers capable of early prediction of
treatment failure, so that patients could be switched earlier to
a different modality.
There is increasing evidence that circulating tumor cells
(CTCs) in blood are an important indicator of the potential for
metastatic disease, poor prognosis, treatment response, and
disease recurrence in breast, colon, prostate, and lung cancers
(de Bono et al., 2008; Krebs et al., 2011; Hou et al., 2012;
Lucci et al., 2012). Similarly, the number of CTCs has been
shown to be prognostic of the overall survival in metastatic
melanoma patients (Khoja et al., 2013).
In melanoma, the most common marker used for CTC
enrichment is the melanoma-associated chondroitin sulphate
proteoglycan (MCSP, HMW-MAA, CSPG4, and NG2;
Faye et al., 2004; Ulmer et al., 2004). In addition, the
CellSearch detection of melanoma CTCs involves the capture
of melanoma cell adhesion molecule (MCAM, CD146, and
MUC18)-expressing cells and immunoﬂuorescence-based
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detection of MCSP-expressing cells (Rao et al., 2011).
However, it has long been appreciated that tumors are
composed of heterogeneous populations, with a pool of cells
that display stem cell properties and drive evolution of the
tumor to a gradually more aggressive phenotype. Recent
studies have shown that CTCs isolated from breast, colon, and
hepatic cancer patient blood are similarly composed of a
heterogeneous pool of tumor cells, some of which have
tumor-initiating/stem cell properties and display epithelial–
mesenchymal transition features and low apoptotic pro-
pensity (Pilati et al., 2012; Baccelli et al., 2013; Sun et al.,
2013). In melanoma, subpopulations of tumor cells with
tumor-initiating/stem cell properties are marked by Nestin
(Grichnik et al., 2006), ATP-binding cassette sub-family B
member 5 (ABCB5; Schatton et al., 2008), CD133 (Monzani
et al., 2007), CD20 (Fang et al., 2005), CD271 (Boiko et al.,
2010), JARID1B (Roesch et al., 2008), and the receptor
activator of NF-κβ (RANK, CD265; Kupas et al., 2011).
We previously demonstrated that immunomagnetic capture
of circulating melanoma cells, using a combination of anti-
bodies to MCAM, MCSP, ABCB5, and CD271, resulted in the
enrichment of larger numbers of cells than when individual
markers were targeted (Freeman et al., 2012). However,
using immunomagnetic beads to isolate CTCs, we could not
identify cells that co-expressed multiple markers, nor could
we determine the proportion of cells expressing particular
marker combinations. To expand our understanding of CTC
expression proﬁles and to identify different CTC subpopula-
tions, here we analyzed whole-blood samples using
multiparametric ﬂow cytometry. Using the melanoma-
associated markers MCAM and MCSP, and the melanoma-
initiating cell markers ABCB5, CD271, and RANK, we
identiﬁed previously unreported CTC subtypes. These sub-
types were compared between patients at early and late
disease stages, as were the dynamics of different CTC
subtypes before and after initiation of treatment with targeted
therapies or immunotherapy. Moreover, we performed a
preliminary evaluation of the potential prognostic value of
these CTC subpopulations.
RESULTS
Marker expression in melanoma cell lines
We ﬁrst evaluated, in several melanoma cell lines, the
expression of the previously identiﬁed CTC markers MCAM,
MCSP, ABCB5, CD271, and RANK (Kupas et al., 2011;
Freeman et al., 2012). A total of nine melanoma cell lines
were analyzed by ﬂow cytometry: seven derived from
metastatic melanoma (C8161, A2058, SK-MEL-2, SK-MEL-5,
UACC62, SK-MEL-28, and MM229) and two derived from
primary melanomas (MM540, MM200). We detected the ﬁve
markers at varying frequencies; MCAM and MCSP were
expressed in 100% of the cells for most cell lines (Figure 1a).
However, MCSP was expressed in only 68% of SK-MEL-5
cells and at lower mean ﬂuorescence intensity than in A2058
cells (Figure 1b). Most cell lines expressed the melanoma stem
cell markers CD271, ABCB5, and RANK at low frequencies.
CD271 was expressed in 70%, 32%, 24%, and 17% of A2058,
SK-MEL-2, SK-MEL-28, and MM229 cells, respectively, but in
o3% of the other ﬁve cell lines. ABCB5 expression was low
(o3%) in most cell lines with only A2058 and MM540
expressing ABCB5 in ~ 13% of cells. RANK was expressed in
both primary melanoma cell lines, 90% of MM540 (Figure 1c)
but in only 23% of MM200. Among metastatic melanoma cell
lines, only MM229 and SK-MEL-2 expressed RANK at 30 and
28%, respectively, whereas it was expressed at low frequen-
cies (o7%) in all other metastatic cell lines (Figure 1a).
Spiking experiments
Prior to performing the analysis of CTCs in the blood from
melanoma patients, we determined the efﬁciency of the ﬂow
cytometric detection method by adding increasing numbers––
i.e., 6, 60, 600, or 6,000 cells of the melanoma cell line
A2058 to 4ml of whole blood from healthy volunteers. Given
that expression of MCAM and MCSP can be readily detected
in 100% of A2058 cells, spiked whole-blood samples were
stained with antibodies speciﬁc for these antigens. After
exclusion of CD45+ and CD34+ cells, melanoma cells were
counted as double-positive for MCAM and MCSP. No double-
positive cells were detected in control blood without
melanoma cells. An average recovery of 85% was obtained
using a direct staining method (Supplementary Figure S1A
and S1B online). The addition of a pre-enrichment step to
deplete CD45-positive cells using the EasySep kit (StemCell)
substantially decreased the recovery rate to o20% (Supple-
mentary Figure S1C online). Given the low numbers of CTCs
found in the blood of most melanoma patients (Freeman et al.,
2012), the direct staining method was selected as the method
of choice.
Identiﬁcation of CTCs by ﬂow cytometry
Blood samples from melanoma patients at early (TNM stages
I–II, N= 16) and late clinical disease stages (TNM stages
III–IV, N=40), and from healthy controls (N= 15) were tested
by multiparameter ﬂow cytometry for the presence of
cells expressing MCSP, MCAM, RANK, ABCB5, or CD271.
Demographic data for the three groups are described in
Table 1. Cells negative for CD45 and CD34 and positive for
any of the ﬁve chosen markers were identiﬁed as CTCs. A
maximum of 10 cells positive for any of the markers were
found among healthy control samples and deﬁned as back-
ground. Blood samples from melanoma patients (all stages
combined) contained a signiﬁcantly larger number of marker-
positive cells (Po0.01). In particular, late-stage patients
had signiﬁcantly more cells compared with healthy controls;
however, this difference was not as apparent for early-stage
patients (Figure 2a).
Co-expression of surface markers on CTCs
We next analyzed the number of CTCs that expressed
different combinations of the ﬁve markers and determined
the co-expression of these markers. The level of background,
deﬁned as the number of marker-positive cells in healthy
controls, varied depending on marker combinations from 0 to
4 cells. Accordingly, the maximum cell number detected in
controls for each marker combination (background) was
subtracted from the respective cell numbers detected in
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melanoma patients. Of the 31 possible marker combinations,
only 9 were identiﬁed among melanoma patients and were
further analyzed in detail. Graphical representation of the
different CTC subtypes present in each patient illustrates the
heterogeneity between the cells found within and between
patients (Figure 2b). CTCs in early-stage patients showed
positivity mainly for a single marker, whereas late-stage
patients had a large number of CTCs and/or their CTCs co-
expressed several markers.
Interestingly, six of the nine marker combinations found in
patients involved the presence of ABCB5, a melanoma
multidrug resistance mediator recently shown to maintain
melanoma-initiating cells (Wilson et al., 2014); however, the
number of cells, as well as the number of patients with those
cells, was low for each independent combination. Taking
together all 6 combinations (including ABCB5 alone),
ABCB5+ cells were found in 13 out of 40 late-stage and 3
out of 16 early-stage patients, accounting for 52% of patients
with detectable CTCs or 29% of all melanoma patients tested.
The RANK+-only subpopulation was the most commonly
detected being found in 46% of all patients. Including
all combinations, RANK+ cells were detected in 22 out of
40 late-stage and 4 out of 16 early-stage patients, accounting
for 84% of patients with detectable CTCs and 46% of all
melanoma patients tested.
MCSP-expressing subpopulations were detected in 10 out
of 40 late-stage and 3 out of 16 early-stage patients,
accounting for 42% of patients with detectable CTCs and
23% of all melanoma patients tested. Samples with
MCAM+MCSP+ cells, either with or without other markers,
were not found in early-stage patients but were present in 6 of
40 late-stage patients (15%).
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Figure 1. Marker expression on the surface of melanoma cell lines. (a) Metastatic and primary melanoma cell lines were tested for the expression of ABCB5,
CD271, RANK, MCSP, and MCAM by ﬂow cytometry. The percentage (mean± SEM) of positive cells obtained in three independent experiments was determined
for each marker. Representative dot plot of ﬂow cytometric staining of (b) MCSP on A2058 and SK-MEL-5 cells or (c) RANK on A2058 and MM540 cells. The
corresponding isotype controls are also depicted. ABCB5, ATP-binding cassette sub-family B member 5; MCAM, melanoma cell adhesion molecule; MCSP,
melanoma-associated chondroitin sulphate proteoglycan; RANK, receptor activator of NF-κβ.
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Among the metastatic melanoma patients analyzed, 22 had
tumors with a mutated BRAF and 16 patients were found to be
wild type for BRAF (Table 1). We analyzed the presence of
CTCs or of a speciﬁc marker combination in relation to the
BRAF status of the patient’s tumor but failed to ﬁnd any
association between these two parameters.
RANK and ABCB5 expression in match tumor tissues
Next we analyzed the expression of RANK and ABCB5 in
metastatic tissue from two patients in which CTCs expressing
these two markers could be detected: patient MM15, in which
100% of detected CTCs were RANK+ and 25% were ABCB5+,
and patient MM26, in which 75% of CTCs were RANK+ but
no ABCB5+ CTCs were detected. The metastases analyzed
were removed from these patients within 1 month prior to
blood collection for CTC analysis. Immunoﬂuorescence
staining of the tissue was performed using antibodies to
MART-1 to deﬁne the tumor cells together with either RANK
or ABCB5 (Figure 3). In contrast with the large percentage
found among CTCs, the number of RANK (~2%) and ABCB5
(6–7.5%)-expressing cells was sparse within the tumor.
Analysis of CTCs during BRAF/MEK-targeted therapy or immune
checkpoint blockade
Of the 40 patients with unresectable metastatic melanoma
enrolled in the study, 29 were tested for the presence of CTCs
before treatment and within 6–13 weeks after therapy
initiation with BRAF/MEK-targeted therapy or immune check-
point blockade. Of these, four individuals were treated with
vemurafenib, ten with a combination of dabrafenib and
trametinib, two with dabrafenib monotherapy, ten with
ipilimumab, two with pembrolizumab, and one with nivolu-
mab. We found no signiﬁcant change in the total number of
CTCs after treatment initiation (Figure 4a). On the basis of our
analysis of CTC subpopulations, we examined each marker
combination as a percentage of total CTCs before and after
therapy. For most populations, no statistically signiﬁcant
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Figure 2. Analysis of circulating tumor cells (CTCs) in melanoma patients
and healthy controls (a) Total number of cells detected in 4ml of whole blood
expressing any of the markers in melanoma patients at late (N= 40) and early
(N=16) stages of the disease and in healthy controls (N=15). The mean is
indicated for each group. An omnibus Kruskal–Wallis test produced a
P-value= 0.07. Mann–Whitney tests were performed and the P-value
indicated for each comparison. (b) Number of cells in 4 ml of blood
corresponding to each CTC subpopulations identiﬁed. Each bar represents a
single melanoma patient. Absent bars represent patients in which CTCs were
not detected. ABCB5, ATP-binding cassette sub-family B member 5; MCAM,
melanoma cell adhesion molecule; MCSP, melanoma-associated chondroitin
sulphate proteoglycan; RANK, receptor activator of NF-κβ.
Table 1. Study participants demographics and clinical
characteristics
Melanoma patients
Healthy
controls
Stages
I–II
Stages
III–IV
N 15 16 40
Age (Range) 54 (26–69) 68 (36–90) 59 (30–85)
Male/female 9/6 13/3 24/16
Stage
I 10
II 6
III 2
IV 38
Number of metastatic sites
0 16
1–2 11
42 29
BRAF status
V600E 13
V600K 7
V600R 1
K601E 1
Wild type 16
Unknown 2
Treatment
Vemurafenib 4
Dabrafenib 2
Dabrafenib/trametinib 14
Ipilimumab 11
Pembrolizumab 4
Nivolumab 1
Others 4
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increase or decrease in their percentage was noticed
(Supplementary Figure S2 online). Interestingly, a statistically
signiﬁcant increase in the percentage of RANK+ cells was
noticed after therapy initiation in patients treated with BRAF-
or BRAF/MEK-targeted therapy (vemurafenib, dabrafenib/
trametinib; Po0.01, Figure 4b). However, this increase was
not apparent among patients treated with checkpoint inhibi-
tors, suggesting that this effect might be speciﬁc to the targeted
therapy treatment.
Prognostic signiﬁcance of speciﬁc CTC subtypes
Of 16 patients treated with targeted therapies (4 vemurafenib,
10 dabrafenib/trametinib, and 2 dabrafenib), 14 individuals
had a reported size reduction in their tumors by Positron
Emission Tomography or Computer Tomography scan at ﬁrst
assessment at around 6 weeks; 12 showed partial responses
and 2 complete responses as per Response Evaluation Criteria
in Solid Tumours (RECIST) 1.1. Of those responding, nine had
controlled tumor growth for 6 months or more, whereas four
experienced tumor relapse within the ﬁrst 6 months after
treatment initiation.
A Kaplan–Meier analysis was performed to determine the
association between CTC presence and prognostic factors
such as response to treatment and progression-free survival
(PFS). Given that the median follow-up time of these patients
was 30 weeks, it is too early to evaluate the predictive value
of the CTC subtypes on overall survival. Exploratory analyses
were performed repeatedly using different cut-off values to
deﬁne a favorable or an unfavorable CTC number, at 1–10
cells (Supplementary Table S1 and S2 online). PFS was not
associated with total CTC counts at baseline or after treatment
initiation (data not shown). Potential association with PFS was
also analyzed in a log-rank test for each of the nine CTC
subtypes (Supplementary Figure S3 online). The presence of
RANK+-only CTCs at baseline did not show statistical
signiﬁcance at any of the cut-off values tested (Figure 4c,
Supplementary Table S1 online). Interestingly, the presence of
RANK+ cells before or after treatment initiation was
signiﬁcantly associated with shorter PFS. The conﬁdence
intervals for the hazard ratios were qualitatively similar at
various cut-off values (Supplementary Table S2 online), with
the difference in PFS between patients with ﬁve or more
RANK-expressing CTCs and those with o5 cells illustrated in
Figure 4d (hazards ratio 8.73, 95% conﬁdence interval 1.82–
41.75, Po0.01).
RANKL/RANK stimulation of melanoma cells affects sensitivity
to vemurafenib
To explore the mechanism of RANK-mediated resistance to
BRAF inhibitors, we selected two melanoma cell lines, A2058
and 1205Lu, and stimulated them with recombinant RANKL
prior to vemurafenib inhibition. A2058 cells express RANK,
MART-1
Pat MM15 Pat MM26
Subcutaneous metastasis (posterior scapular region) Liver metastasis
MART-1 MART-1 MART-1
ABCB5RANKRANK
RANK MART-1 RANK MART-1
ABCB5
ABCB5 MART-1 ABCB5 MART-1
Figure 3. Receptor activator of NF-κβ (RANK) and ATP-binding cassette sub-family B member 5 (ABCB5) expression in metastases from patients with
circulating tumor cells (CTCs) expressing these markers. Immunoﬂuorescence staining of metastatic melanoma tissue corresponding to patients MM15 (a) and
MM26 (b). MART-1 staining was used to identify melanoma cells. Original magniﬁcation × 400. Scale bar=20 μm.
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albeit at low frequency. On the other hand, 1205Lu cells do
not express RANK by ﬂow cytometry or by reverse
transcriptase–PCR (data not shown). Pre-incubation with
RANKL did not affect the sensitivity to vemurafenib of
1205Lu cells (Figure 5a). Conversely, A2058 cell stimulation
with 2.5 μgml−1 RANKL, but not 0.5 μg ml− 1 RANKL,
showed less sensitivity to vemurafenib than unstimulated
cells (Figure 5a and b).
DISCUSSION
We previously demonstrated that a multi-marker approach
enhances the isolation of CTCs in melanoma (Freeman et al.,
2012). Here we further support this multi-targeted CTC
detection approach by identifying for the ﬁrst time cellular
heterogeneity of CTCs within and among melanoma patients.
Moreover, we provide evidence that distinct CTC subpopula-
tions are differentially affected by alternate melanoma therapies.
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Figure 4. Prognostic signiﬁcance of RANK+ cells. (a) Total CTC counts and (b) the percentage of CTCs expressing MCAM-MCSP-CD271-ABCB5-RANK+ were
quantiﬁed in 29 patients with unresectable metastatic melanoma at baseline and 6–13 weeks after treatment initiation. Open circles indicate patients treated with
immunotherapy (N= 13); ipilimumab (N= 10), pembrolizumab (N= 2), and nivolumab (N= 1). Black circles indicate patients treated with targeted therapies
(N=16); vemurafenib (N=4), dabrafenib/trametinib (N=10), and dabrafenib (N=2). The P-values of Wilcoxon matched-pairs signed rank tests are indicated for
each comparison. (c and d) Kaplan–Meier curves for progression-free survival of metastatic melanoma patients undergoing targeted therapies (N=16). Patients
were stratiﬁed as those with ⩾5 ando5 RANK+ cells in 4 ml of blood at (c) baseline (before therapy) and (d) after therapy initiation. The long rank P-values are
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Here we found MCAM+MCSP+ CTCs in 15% of patients,
exclusively in those with late-stage melanoma. This is
consistent with the report of Khoja et al. (2013) using the
CellSearch system for identiﬁcation of CTCs. The addition of
tumor initiation markers to the panel increased the frequency
(62%) and the number of cells detected in late-stage
melanoma. Moreover, CTCs were also detected in a pro-
portion of early-stage cases. The prognostic relevance of
the presence of these markers in patients with localized
melanoma needs to be explored in large prospective studies
powered to address this important question.
A relevant observation derived from our study is the large
proportion of detected CTCs expressing stem cell markers.
This is consistent with our previous observations that addition
of stem cell markers for immunocapture of CTCs increases the
number of detected cells (Freeman et al., 2012) and that BRAF
V600E mutations can be detected in CTCs enriched with
antibodies to ABCB5 and RANK (Reid et al., 2014). The
frequency of cells expressing ABCB5 and RANK is rather low
in the tumor tissue, as shown here as well as in previous
studies (Schatton et al., 2008; Kupas et al., 2011). This is
consistent with the observations by Ma et al. (Ma et al., 2010)
in which a larger proportion of the CTCs found in mouse
blood expressed ABCB5 in comparison with the corres-
pondent tumor tissue. This enrichment of stem-like cells
among the CTC pool suggests a selective process through
which melanoma-initiating cells preferentially reach the
circulation. Alternatively, environmental conditions within
the blood induce the expression of these markers. This
enrichment in the blood of cancer cells with higher tumor
initiation potential is a critical phenomenon for metastatic
spreading and warrants further investigation.
Interestingly, the percentage of RANK+ cells increased after
therapy initiation in patients treated with BRAF inhibitors.
Moreover, the presence of these RANK+ cells was associated
with shorter PFS in patients treated with BRAF inhibitors.
Comparison with a similar cohort of patients treated with
immune checkpoint blockade indicates that this increase in
RANK+ CTCs is speciﬁc to the treatment with MAPK
inhibitors. Nevertheless, larger studies are needed to corro-
borate this observation. Moreover, it is important to elucidate
the mechanism through which the RANKL/RANK axis affects
MAPK inhibition in melanoma.
The relevance of RANK expression in melanoma has not
been studied in detail. Kupas et al. (2011) identiﬁed hetero-
geneous expression of RANK in cells from tumors and
peripheral blood from melanoma patients. The authors
found a large number of RANK+ cells in the blood of some
melanoma patients consistent with our observation. Moreover,
they demonstrated that RANK+ CTCs had an enhanced
tumor-initiating capacity in immunodeﬁcient mice. This is
consistent with reports in breast cancer where RANK over-
expression and RANKL stimulation induce epithelial-
mesenchymal-transition and stemness in human mammary
epithelial cells and promote tumorigenesis and metastasis
(Palafox et al., 2012).
Our preliminary results into the role of RANK in BRAF
inhibition suggest that stimulation through the RANK/RANKL
axis results in a decreased sensitivity to vemurafenib. A recent
study showed that activation of NF-κβ is associated with a
distinct melanoma cell state with an intrinsic resistance to
MAPK inhibitors (Konieczkowski et al., 2014); thus, RANK-
mediated activation of NF-κβ could lead the cells to a similar
state. Moreover, RANKL/RANK stimulation via TRAF6 is
known to activate JNK1, AKT/PKB, and p44/42 ERK, (Palafox
et al., 2012), all of which could bypass BRAF inhibition resulting
in decreased drug sensitivity. Further studies into the mechanism
behind this RANK-mediated resistance in melanoma cells
warrant further studies.
Kupas et al. showed that most RANK-expressing cells also
expressed the melanoma stem cell markers ABCB5 and
CD133 (Kupas et al., 2011). Previous research has shown that
treatment of three melanoma cell lines with vemurafenib and
to lesser extent dacarbazine resulted in an increase in ABCB5-
positive cells (Chartrain et al., 2012). Across our study, we
found RANK+ CTCs also expressing ABCB5 in 14 out of 40
metastatic patients with RANK+ CTCs. It is known that
chemotherapies preferentially eliminate rapidly dividing
cells (Blagosklonny, 2005). Indeed, survival of a subpo-
pulation of slow-cycling melanoma cells expressing JARID1B
after vemurafenib treatment has been recently described
(Roesch et al., 2013). Future studies are needed to assert
whether RANK is an alternative marker of slow cycling cells
and reduced sensitivity to the MAPK pathway inhibitors.
Our results underscore the importance of determining the
prognostic value of different CTC subpopulations. In parti-
cular, the observed increase in a CTC subpopulation upon
treatment further supports a multi-marker approach for
capturing melanoma CTCs in order to monitor treatment
responses. The analysis of CTCs may provide a suitable
strategy to study, in real time, the pharmacokinetics of
resistance in metastatic melanoma and evaluate therapeutic
strategies to overcome drug resistance.
MATERIALS AND METHODS
Patient blood samples
Patients, recruited from 3 clinics in Perth, Western Australia, were
diagnosed and staged according to guidelines of the American Joint
Committee on Cancer. Patients were recruited between October
2012 and May 2014. Peripheral blood samples were obtained from
16 non-metastatic patients (TNM stages I and II) within 2 weeks of
removal of the primary melanoma lesion. Blood from 40 metastatic
melanoma patients (TNM stages III and IV) was obtained prior to
commencement of treatment. In addition, blood samples were
analyzed during treatment for 22 metastatic melanoma patients. In
addition, blood samples were obtained from 15 healthy volunteers.
Blood was drawn by phlebotomists into BD Vacutainer K2 EDTA
tubes (BD Biosciences, San Jose, CA), after the ﬁrst few milliliters
were discarded to avoid epithelial contamination, and refrigerated at
4 °C until used. Samples were processed within 48 hours from
collection time. Participants signed informed consent with the
clinician in accordance with the protocols safeguarding patient
rights. All procedures have been accepted by the Human Research
Ethics Committees at Edith Cowan University (No. 2932) and
Sir Charles Gairdner Hospital (No. 2007-123).
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Flow cytometric staining
For detection of CTCs, two vials of 4 mls of blood samples were
treated with an isotonic solution (140 mM NH4Cl, 17 mM Tris, pH
7.65) for red blood cell lysis, followed by a wash in FACS buffer
(0.1% bovine serum albumin, 100mM EDTA, 10mM HEPES,
phosphate-buffered saline). One sample was stained with antibodies
to CD45-APC.AF750, CD34-AF700, MCSP-APC, MCAM-PE.Cy7,
CD271-PerCPCy5.5, ABCB5-PE.TxRed, and RANK-PE, and the
second sample was stained with the CD45 and CD34 antibodies
and isotype controls for APC, PE.Cy7, PerCPCy5.5, PE.TxRed, and
PE. Antibodies were incubated with the cells for 30 minutes at 4 °C.
After washing out unbound antibodies, dead cells were stained using
the Green Dead Cell Stain Kit (LifeTechnologies, Carlsbad, CA) for
15 minutes at 4 °C. After two washes with FACS buffer, cells were
immediately acquired in a Gallios ﬂow cytometer (Beckman Coulter,
Miami, FL). Data were processed using Kaluza Analysis Software
(Beckman Coulter). Gates were delineated using the isotype controls
to obtain a minimum background signal.
Melanoma cell lines were removed from the culture ﬂask at 80%
conﬂuence using 2mM EDTA and 2× 105 cells were stained for ﬂow
cytometric analysis as described above, except for the CD45 and
CD34 staining.
The recovery of CTCs after a pre-enrichment of CD45-negative
cells was evaluated using spiked blood. CD45-positive cells were
depleted using the EasySep kit (StemCell Technologies, Vancouver,
BC) following the manufacturer’s instructions. Peripheral blood
mononuclear cells were isolated in Ficoll-Paque plus (GE healthcare,
Milwaukee, WI) and washed once with red blood cell lysing buffer
and twice with 2% fetal bovine serum/phosphate-buffered saline,
prior to incubation with CD45 depletion cocktail.
Statistical analysis
As data did not pass the Kolmogorov-Smirnov test for normal
distribution, the non-parametric Mann–Whitney U-test and the
Wilcoxon matched-pairs signed-rank test were used where appro-
priate. The number of CTCs within each subtype was dichotomized
in order to determine the best cut-off value to discriminate between
groups with a favorable and an unfavorable PFS. Survival curves
were plotted using the Kaplan–Meier method and the log rank test
using GraphPad Prism 5 for Windows (La Jolla, CA), and univariate
Cox proportional hazards regression analyses were performed to
evaluate the prognostic value of CTC subpopulations for PFS using
the Statistical Package for Social Sciences for Window version 22
(SPSS, Chicago, IL). The reported P-values have not been adjusted for
multiple comparisons. Tumor responses were assessed radiologically
at 2 to 3 monthly intervals. CT scans were assessed by the RECIST 1.1
criteria and classiﬁed as having a complete response, partial
response, stable disease, or progressive disease. Response time was
calculated from the date at baseline to the date of ﬁrst reported partial
response or complete response. PFS time was calculated from
baseline date to the date of ﬁrst reported progressive disease.
Drug sensitivity and RANKL stimulation
Cell proliferation inhibition experiments were performed in a 96-well
plate in triplicate. Cells were seeded at 104 cells per well and
stimulated for 24 hours with rRANKL at 2.5 μgml− 1, 0.5 μgml−1 or
left unstimulated. After 12 hours of stimulation, cells were treated
with serial dilutions of vemurafenib/PLX4032 for 72 hours. Viable
cells were qualiﬁed using the CellTiter-GLO Luminescence Kit
(Promega, Madison, WI) following the manufacturer’s instructions.
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